CD19 and glioblastoma: IGFBP2 induced immunosuppression by decreasing CD8+ T and CD19+ B cells and increasing CD163+ M2 TAMs; blocking this gene suppressed tumor growth and improved survival in a glioblastoma mouse model [43].